Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry

Authors

  • Henrik H. P. Larsen Department of Dermatology, Copenhagen University Hospital – Bispebjerg and Frederiksberg, Copenhagen, Denmark and Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark
  • Ida Vittrup
  • Iben F. Ruge
  • Jesper Elberling
  • Lone Skov
  • Kristina Ibler
  • Gregor B. E. Jemec
  • Charlotte G. Mortz
  • Rasmus O. Bach
  • Carsten Bindslev-Jensen
  • Maiken G. Dalager
  • Tove Agner
  • Mette Deleuran
  • Christian Vestergaard
  • Jacob P. Thyssen Department of Dermatology, University of Copenhagen, Bispebjerg Hospital, Bispebjerg Bakke 23, DK-2400 Copenhagen, Denmark

DOI:

https://doi.org/10.2340/actadv.v102.915

Keywords:

atopic dermatitis, baricitinib, dupilumab, real-world, registry, treatment

Abstract

Data from real-world use of new systemic treatments in atopic dermatitis (AD) is important for assessing safety and efficacy. The aim of this study is to describe the baseline characteristics of adult patients with moderate-to-severe AD enrolled in the Danish nationwide Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH) database, between October 2017 and August 2021. A total of 282 adult patients were included. Most (62%) were men, the median age at baseline was 43 years (interquartile range (IQR) 29–54 years), and median age at onset of AD was 1 year (IQR 0–6 years). The median Eczema Area and Severity Index at treatment initiation was 19.1 (IQR 11.9–25.7); median Patient Oriented Eczema Measure 21.0 (IQR 16.0–25.0); median Dermatology Life Quality Index 13.0 (IQR 7.0–19.0); and median itch and sleep numerical rating scale scores 8.0 (IQR 6.0–9.0) and 6.0 (IQR 4.0–8.0). Differences were found between the sexes. This registry will provide a source for future efficacy and safety studies. 

Downloads

Download data is not yet available.

References

Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy 2014; 2014: 354250.

https://doi.org/10.1155/2014/354250

Thyssen JP, Corn G, Wohlfahrt J, Melbye M, Bager P. Retrospective markers of paediatric atopic dermatitis persistence after hospital diagnosis: a nationwide cohort study. Clin Exp Allergy 2019; 49: 1455-1463.

https://doi.org/10.1111/cea.13487

Blome C, Radtke MA, Eissing L, Augustin M. Quality of life in patients with atopic dermatitis: disease burden, measurement, and treatment benefit. Am J Clin Dermatol 2016; 17: 163-169.

https://doi.org/10.1007/s40257-015-0171-3

Tan RA, Corren J. The relationship of rhinitis and asthma, sinusitis, food allergy, and eczema. Immunol Allergy Clin North Am 2011; 31: 481-491.

https://doi.org/10.1016/j.iac.2011.05.010

Narla S, Silverberg JI. Association between atopic dermatitis and autoimmune disorders in US adults and children: a cross-sectional study. J Am Acad Dermatol 2019; 80: 382-389.

https://doi.org/10.1016/j.jaad.2018.09.025

Sun D, Ong PY. Infectious complications in atopic dermatitis. Immunol Allergy Clin North Am 2017; 37: 75-93.

https://doi.org/10.1016/j.iac.2016.08.015

Rønnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol 2018; 79: 448-456.

https://doi.org/10.1016/j.jaad.2018.03.017

Deleuran M, Carlsen B, Thomsen SF, Holm E, Mørtz C, Vestergaard C. Udredning og behandling af patienter med atopisk dermatitis [Diagnosis and treatment of patients with atopic dermatitis, In Danish] [cited 2022 Mar 7]. Available from: https://dds.nu/wp-content/uploads/2020/11/AD-guideline-oktober-2020.pdf.

Napolitano M, Fabbrocini G, Cinelli E, Stingeni L, Patruno C. Profile of baricitinib and its potential in the treatment of moderate to severe atopic dermatitis: a short review on the emerging clinical evidence. J Asthma Allergy 2020; 13: 89-94.

https://doi.org/10.2147/JAA.S206387

Pedersen KM, Andersen JS, Snødergaard J. General practice and primary health care in Denmark. J Am Board Fam Med 2012; 25: S34-S38.

https://doi.org/10.3122/jabfm.2012.02.110216

Gerner T, Haugaard JH, Vestergaard C, Deleuran M, Jemec GB, Mortz CG, et al. Healthcare utilization in Danish children with atopic dermatitis and parental topical corticosteroid phobia. Pediatr Allergy Immunol 2021; 32: 331-341.

https://doi.org/10.1111/pai.13394

Spuls PI, Gerbens LAA, Apfelbacher CJ, Wall D, Arents BWM, Barbarot S, et al. The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: an initiative to harmonize data collection across national atopic eczema photo- and systemic therapy registries. J Invest Dermatol 2017; 137: 2014-2016.

https://doi.org/10.1016/j.jid.2017.05.014

Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Daudén E, Sánchez-Carazo JL, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol 2012; 148: 463-470.

https://doi.org/10.1001/archdermatol.2011.2768

Vatrella A, Fabozzi I, Calabrese C, Maselli R, Pelaia G. Dupilumab: a novel treatment for asthma. J Asthma Allergy 2014; 7: 123-130.

https://doi.org/10.2147/JAA.S52387

Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 2019; 393: 2303-2311.

https://doi.org/10.1016/S0140-6736(19)30419-2

Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014; 20: 1043-1049.

https://doi.org/10.1038/nm.3645

Hick J, Feldman SR. Eligibility creep: a cause for placebo group improvement in controlled trials of psoriasis treatments. J Am Acad Dermatol 2007; 57: 972-976.

https://doi.org/10.1016/j.jaad.2007.08.008

Bosma AL, de Wijs LEM, Hof MH, van Nieuwenhuizen BR, Gerbens LAA, Middelkamp-Hup MA, et al. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. J Am Acad Dermatol 2020; 83: 1375-1384.

https://doi.org/10.1016/j.jaad.2020.05.128

Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz JD, Reguiai Z, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 2019; 81: 143-151.

https://doi.org/10.1016/j.jaad.2019.02.053

Nettis E, Ferrucci S, Ortoncelli M, Pellacani G, Foti C, Di Leo E, et al. Use of dupilumab for 543 adult patients with moderate-to-severe atopic dermatitis: a multicenter, retrospective study. J Investig Allergol Clin Immunol 2020; 32: 1-28.

https://doi.org/10.18176/jiaci.0641

Ariëns LFM, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-week results from the Dutch BioDay registry. J Am Acad Dermatol 2021; 84: 1000-1009.

https://doi.org/10.1016/j.jaad.2020.08.127

Siegels D, Haufe E, Heinrich L, Werfel T, Weidinger S, Schmitt J, et al. Status report on the atopic dermatitis registry TREATgermany. Allergol Sel 2021; 5: 274-286.

https://doi.org/10.5414/ALX02262E

Heratizadeh A, Haufe E, Stölzl D, Abraham S, Heinrich L, Kleinheinz A, et al. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. J Eur Acad Dermatology Venereol 2020; 34: 1263-1272.

https://doi.org/10.1111/jdv.16078

Andersen YMF, Egeberg A, Skov L, Thyssen JP. Demographics, healthcare utilization and drug use in children and adults with atopic dermatitis in Denmark: a population-based cross-sectional study. J Eur Acad Dermatology Venereol 2019; 33: 1133-1142.

https://doi.org/10.1111/jdv.15424

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335-2348.

https://doi.org/10.1056/NEJMoa1610020

Silverberg JI, Lei D, Yousaf M, Janmohamed SR, Vakharia PP, Chopra R, et al. Association of itch triggers with atopic dermatitis severity and course in adults. Ann Allergy, Asthma Immunol 2020; 125: 552-559.

https://doi.org/10.1016/j.anai.2020.06.014

Nyrén M, Lindberg M, Stenberg B, Svensson M, Svensson Å, Meding B. Influence of childhood atopic dermatitis on future worklife. Scand J Work Environ Heal 2005; 31: 474-478.

https://doi.org/10.5271/sjweh.952

van Os-Medendorp H, Appelman-Noordermeer S, Bruijnzeel-Koomen C, de Bruin-Weller M. Sick leave and factors influencing sick leave in adult patients with atopic dermatitis: a cross-sectional study. J Clin Med 2015; 4: 535-547.

https://doi.org/10.3390/jcm4040535

Ariëns LFM, Bakker DS, Spekhorst LS, Van der Schaft J, Thijs JL, Haeck I, et al. Rapid and sustained effect of dupilumab on work productivity in patients with difficult-to-treat atopic dermatitis: results from the Dutch BioDay Registry. Acta Derm Venereol 2021; 101: adv00573.

https://doi.org/10.2340/00015555-3886

Downloads

Additional Files

Published

2022-08-24

How to Cite

Hedegaard Pliess Larsen, H., Vittrup, I., Frier Ruge, I., Elberling, J., Skov, L., Ibler, K., Borut Ernst Jemec, G., Gotthard Mørtz, C., Overgaard Bach, R., Bindslev-Jensen, C., Glud Dalager, M., Agner, T., Deleuran, M., Vestergaard, C., & Pontoppidan Thyssen, J. (2022). Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry. Acta Dermato-Venereologica, 102, adv00760. https://doi.org/10.2340/actadv.v102.915

Issue

Section

Articles

Categories